Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
Breast Cancer
DRUG: Cetuximab|DRUG: Docetaxel
Pathological complete response assessment of Taxotere-Erbitux combination, After 18 weeks of treatment
Clinical, mammographic and ultrasound response Breast cancer conservation rate Overall and disease free survival Safety to treatments, After 18 weeks of treatment, at surgery and at five years (survival)
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".